Although the incidence of most harm outcomes was consistent across the specific GLP-1 RAs, some were specific, such as alopecia (observed in tirzepatide) and cholecystitis (observed only in tirzepatide and liraglutide), leading to between-treatment variations in net benefit (Table 2). The gene discussed is GCG; the disease is Cholecystitis.